Predict your next investment

Tempus company logo
HEALTHCARE | Biotechnology

See what CB Insights has to offer

Founded Year



Series G - II | Alive

Total Raised




Last Raised

$200M | 9 mos ago

About Tempus

Tempus builds a library of molecular and clinical data as well as a corresponding operating system for data accessibility and use. The company enables physicians to deliver personalized cancer care for patients through its interactive analytical and machine learning platform. It provides genomic sequencing services and molecular and therapeutic data analysis to empower physicians to make real-time, data-driven decisions.

Tempus Headquarter Location

600 West Chicago Avenue Suite 510

Chicago, Illinois, 60654,

United States


Latest Tempus News

Cedars-Sinai Cancer Launches ‘Molecular Twin’ Initiative for Precision Cancer Treatment

Sep 10, 2021

What You Should Know: – Cedars-Sinai Cancer and Tempus , a provider of artificial intelligence and precision medicine, are harnessing the power of big data and AI to design personalized cancer treatment options by creating virtual replicas of patients’ DNA, RNA, protein and other information to help identify the most effective approach to each individual’s disease. – By creating these “molecular twins,” scientists can genetically classify cancer genes and proteins of particular tumors obtained from thousands of Cedars-Sinai cancer patients to build a database that will be mined by investigators, including those outside Cedars-Sinai. The Molecular Twin initiative also will advance cancer care and research in underserved populations and enable investigators to analyze how ethnic and racial disparities affect tumor biology and treatment among diverse populations. Molecular Twin Database The Molecular Twin database will integrate and store “de-identified” clinical and molecular patient information to ensure that patients and their physicians have access to individualized cancer care strategies, risk assessments, treatments and novel clinical trials. This patient information-stripped of personal details-also will be available to researchers to offer insight into why some patients are resistant to certain therapies and provide data for potential cancer discoveries, including new treatments. “Molecular twins serve as scientific stunt doubles that are always in the lab, ready to identify the best current therapies and, perhaps, reveal important details of how a cancer will affect the patient,” said Dan Theodorescu, MD, PhD, director of Cedars-Sinai Cancer, who conceived of and leads the initiative. “We hope that in the long term, the scientific convergence of multiple biologic, physical and computational datasets on thousands of patients will enable us to develop the treatments of tomorrow as we discover the circuitry used by cancer and other abnormal cells to drive the disease. That is the dream.” Leveraging Tempus’ Next-Gen Platform As part of the collaboration, Cedars-Sinai will deploy Tempus’ next-generation DNA and RNA sequencing tests, which produce high-quality molecular data to identify each patient’s actionable genetic mutations and associated therapies and potential clinical trials, throughout their cancer journey. Tempus’ AI-enabled diagnostic tests match molecular and clinical data to contextualize patients’ reports, providing physicians with data to help personalize care in real time, including evaluation of DNA with mutations shed by cancers and circulating in a patient’s blood. EHR Integration In addition, Tempus’ tests to sequence a collection of specific patient populations as part of its research-based projects. Simultaneously, Tempus is integrating with the Cedars-Sinai Epic EHR system to structure its clinical data, including clinical notes, lab reports, pathology images and radiology scans, making the information easily accessible to both physicians and researchers. This work powers the Molecular Twin archive of de-identified data, which aims to advance research and discovery. Cedar Patients’ Molecular Twins  Workflow Under the Molecular Twin project, patients will be seen in the clinic, where a physician will take multiple biological samples from tumors, other tissues and blood. Those samples and other clinical data will be analyzed by Cedars-Sinai and Tempus, which will identify markers that predict the way the disease might respond to treatment and provide the patient and physician with a comprehensive molecular report. Based on the report, physicians will receive customized treatment information, which will include standard therapy options. If no standard therapy is indicated, physicians will consider the information in the Molecular Twin profile to select the best clinical trial for a patient. The patient’s molecular twin will be stored in the database, along with thousands of others, for current and future study by investigators. The patients’ molecular twins also will be progressively annotated and enriched with each medical visit, providing useful data on their medical journeys.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Tempus

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Tempus is included in 6 Expert Collections, including Genomics.



823 items

Companies involved in the capture, sequencing, and/or analysis of genetic data


Unicorns- Billion Dollar Startups

818 items


Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.


AI 100 2018

99 items


Artificial Intelligence ( AI ) in Healthcare

826 items

These healthcare startups are using AI to discover new drugs, remotely monitor patients, securely transfer patient data, and more.


Clinical Trials Tech

424 items

Companies developing products and services to streamline drug R&D, from drug discovery, pre-clinical testing, and clinical trials.

Tempus Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Tempus Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.